Protein C News and Research

RSS

Champions Biotechnology and Ramot establish licensing agreement

Champions Biotechnology, Inc., a U.S. Oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.

2 Dec 2009

NHLBI awards stimulus funds for hemophilia drug research

PTC Therapeutics, Inc. (PTC) today announced the receipt of a $1 million Challenge Grant award from the National Heart, Lung, and Blood Institute (NHLBI) as part of the National Institutes of Health (NIH).

2 Dec 2009

Protein marker may hold the key against pancreatic cancer

Pancreatic tumors can be identified by a readily detectable marker that shows promise as a basis for immune therapy against the disease, according to research at Washington University School of Medicine in St. Louis.

2 Dec 2009

A leader in the fight against brain diseases and in drug discovery joins UF

A leader in the fight against brain diseases and in drug discovery to help Alzheimer's patients has joined the University of Florida College of Medicine, interim dean Michael Good, M.D., announced.

2 Dec 2009

Protein ERK oscillates between two major compartments in breast tissue cells

Time-lapsed video of individual breast tissue cells reveals a never-before-seen event in the life of a cell: a protein that cycles between two major compartments in the cell. The results give researchers a more complete view of the internal signals that cause breast tissue cells to grow, events that go awry in cancer and are targets of drug development.

2 Dec 2009

Human Melanoma Research Team pursuing identification of anti-tumor prognostic markers and drugs

The constant increase in the rate of cutaneous melanoma over recent years and its resistance to anti-tumour pharmaceutical drugs has meant that the study of cutaneous melanoma is one of the greatest scientific challenges in the field of cancer. The Human Melanoma research team at the University of the Basque Country (UPV/EHU) is focusing on this study.

2 Dec 2009

Development of novel virus can lead to new therapeutic strategy to combat cancer

Ohio State University cancer researchers have developed a tumor-attacking virus that both kills brain-tumor cells and blocks the growth of new tumor blood vessels.

2 Dec 2009

Bioactive sponge to eliminate normally fatal tumors

InCytu Incorporated, a therapeutic device engineering company, announced the details of its Cellarium™ Cancer Vaccine program. Cellarium™ is a small bioactive sponge which regulates dendritic cells and T-cells to eliminate normally fatal tumors in a preclinical model of late stage melanoma. The details of such a promising new vaccine were published for the first time in Science’s Translational Medicine Journal.

2 Dec 2009

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

The Burrill Biotech Select Index managed to claw back almost half the value it lost in October. The Select's gain of 4.5 percent mirrored what was also an excellent month for the general markets with the Dow up 6.5 percent and the NASDAQ up 4.8 percent in value.

2 Dec 2009

Researchers develop new application for improved detection of breast cancer cells

Single-walled nanotubes—cylinders of carbon about a nanometer in diameter—have been highly touted for potential applications such as ultrastrong fibers, electrical wires in molecular devices, or hydrogen storage components for fuel cells. Thanks to a new development by researchers at the National Institute of Standards and Technology (NIST) and five partners, you can add one more application to the list: detection and destruction of an aggressive form of breast cancer.

2 Dec 2009

DiaMedica to acquire all issued and outstanding shares of Sanomune

DiaMedica Inc. (TSX VENTURE:DMA)("Diamedica"), a biopharmaceutical company that has discovered and is developing a novel approach to treating diabetes, announces it has entered into a non-binding letter of intent to acquire all of the issued and outstanding shares of Sanomune Inc.

2 Dec 2009

CRi announces study results of imaging and analysis platform for drug and molecular diagnostic development

Cambridge Research & Instrumentation, Inc. (CRi), a leader in biomedical imaging, today announced the results of a study demonstrating for the first time the capability to detect and automatically measure key activity indicators of cancer cell signal transduction pathways in intact tissue.

2 Dec 2009

TGF--1 suppresses the growth of cancer cells, find researchers

UT Southwestern Medical Center researchers have found that a naturally occurring protein -- transforming growth factor beta1 (TGF--1) -- which normally suppresses the growth of cancer cells, causes a rebound effect after a prolonged exposure.

2 Dec 2009

New scientific breakthrough may allow doctors to reverse cleft palate in humans

In a study newly published in the journal Development, investigators at the USC School of Dentistry describe how to non-surgically reverse the onset of cleft palate in fetal mice - potentially one step in the journey to a better understanding of similar defects in humans.

2 Dec 2009

Canadians with hemophilia A can use new treatment option, XYNTHA

Canadians with hemophilia A - a rare, inherited blood-clotting disorder - now have a new treatment option with the introduction of XYNTHA(TM), a recombinant factor VIII product for both the control and prevention of bleeding episodes and surgical prophylaxis.

2 Dec 2009

Antipsychotic medications increase the levels of inflammation markers, find researchers

Overall, antipsychotic medications are reasonably effective, and fairly well tolerated treatments for mood and psychotic disorders. However, treatment with a number of antipsychotic medications is associated with weight gain, and for some, hyperglycemia and hyperlipidemia.

2 Dec 2009

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced that results from preclinical and clinical studies of two, novel blood forming agents, ACE-011 and ACE-536, will be presented at the 51st Annual Meeting of the American Society of Hematology at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

1 Dec 2009

Pfizer, Protalix team up to develop and market plant-based enzyme for Gaucher’s disease treatment

Pfizer and Protalix (NYSE-Amex: PLX) today announced that they have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of Gaucher’s disease.

1 Dec 2009

TAP and pharma company team up to design Sonata, a unique system to speed drug development

The Automation Partnership (TAP), a world leader in the design and development of innovative automation for life science applications, is delighted to announce that its Advanced Projects Group has partnered with a leading pharma company to successfully design and deliver Sonata™, a unique system for automated culturing and processing of cell lines in shake flasks.

1 Dec 2009

Researchers identify better strategies to control weight in adolescents

Adolescent obesity is a major public health problem that impacts one out of every three children, resulting in 4-5 million overweight youth in the United States.

1 Dec 2009

Protein C News and Research

Champions Biotechnology and Ramot establish licensing agreement

NHLBI awards stimulus funds for hemophilia drug research

Protein marker may hold the key against pancreatic cancer

A leader in the fight against brain diseases and in drug discovery joins UF

Protein ERK oscillates between two major compartments in breast tissue cells

Human Melanoma Research Team pursuing identification of anti-tumor prognostic markers and drugs

Development of novel virus can lead to new therapeutic strategy to combat cancer

Bioactive sponge to eliminate normally fatal tumors

Burrill Biotech Select Index manages to claw back almost half the value it lost in October

Researchers develop new application for improved detection of breast cancer cells

DiaMedica to acquire all issued and outstanding shares of Sanomune

CRi announces study results of imaging and analysis platform for drug and molecular diagnostic development

TGF--1 suppresses the growth of cancer cells, find researchers

New scientific breakthrough may allow doctors to reverse cleft palate in humans

Canadians with hemophilia A can use new treatment option, XYNTHA

Antipsychotic medications increase the levels of inflammation markers, find researchers

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Pfizer, Protalix team up to develop and market plant-based enzyme for Gaucher’s disease treatment

TAP and pharma company team up to design Sonata, a unique system to speed drug development

Researchers identify better strategies to control weight in adolescents

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News